BioCentury | Sep 29, 2020
Distillery Therapeutics

Repeat expansion-targeting antisense oligo for ALS and frontotemporal dementia

...antisense oligo targeting G4C2 repeats —provided by Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

...C9orf72 protein to treat ALS or FTD. Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...antibodies in clinical testing and is partnered with Ionis Pharmaceuticals Inc....
BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

...patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi inotersen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc....
BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...has seen eight new senior management appointments and three internal promotions in less than a year.Ionis Pharmaceuticals Inc....
...Ionis being the most active dealmaker at 18 total deals.TARGETSANGPTL3 – Angiopoietin-like 3 Amanda Micklus Akcea Therapeutics Inc. Ionis Pharmaceuticals Inc. Antisense acquisition...
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

...this program from TMS Co. Ltd. **Biogen has an option to acquire this program from Ionis Pharmaceuticals Inc....
...Thursday’s deal is Biogen’s second for a therapy targeting LRRK2. The company is collaborating with Ionis Pharmaceuticals Inc....
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...debuted in May with $100 million in funding, three clinical programs and a partnership with Ionis Pharmaceuticals Inc....
BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

...is being submitted for FDA review; and vupanorsen, a ligand-conjugated antisense therapy against ANGPTL3 from Ionis Pharmaceuticals Inc....
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

...as SCN8A epilepsy, and migraine. Outside of its small molecule pipeline, Praxis is partnered with Ionis Pharmaceuticals Inc....
...Goldstein and Steven Petrou University collaborators: Florey Institute of Neuroscience and Mental Health Corporate partners: Ionis Pharmaceuticals Inc....
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

...B and has “several” other candidates ready for IND submission. Ribo is also partnered with Ionis Pharmaceuticals Inc....
Items per page:
1 - 10 of 1429
BioCentury | Sep 29, 2020
Distillery Therapeutics

Repeat expansion-targeting antisense oligo for ALS and frontotemporal dementia

...antisense oligo targeting G4C2 repeats —provided by Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

...C9orf72 protein to treat ALS or FTD. Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...antibodies in clinical testing and is partnered with Ionis Pharmaceuticals Inc....
BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

...patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi inotersen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc....
BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...has seen eight new senior management appointments and three internal promotions in less than a year.Ionis Pharmaceuticals Inc....
...Ionis being the most active dealmaker at 18 total deals.TARGETSANGPTL3 – Angiopoietin-like 3 Amanda Micklus Akcea Therapeutics Inc. Ionis Pharmaceuticals Inc. Antisense acquisition...
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

...this program from TMS Co. Ltd. **Biogen has an option to acquire this program from Ionis Pharmaceuticals Inc....
...Thursday’s deal is Biogen’s second for a therapy targeting LRRK2. The company is collaborating with Ionis Pharmaceuticals Inc....
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...debuted in May with $100 million in funding, three clinical programs and a partnership with Ionis Pharmaceuticals Inc....
BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

...is being submitted for FDA review; and vupanorsen, a ligand-conjugated antisense therapy against ANGPTL3 from Ionis Pharmaceuticals Inc....
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

...as SCN8A epilepsy, and migraine. Outside of its small molecule pipeline, Praxis is partnered with Ionis Pharmaceuticals Inc....
...Goldstein and Steven Petrou University collaborators: Florey Institute of Neuroscience and Mental Health Corporate partners: Ionis Pharmaceuticals Inc....
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

...B and has “several” other candidates ready for IND submission. Ribo is also partnered with Ionis Pharmaceuticals Inc....
Items per page:
1 - 10 of 1429